Pfizer to combine off-patent drug business with Mylan

Pfizer to combine off-patent drug business with Mylan

  • 29-Jul-2019

Pfizer announced Monday it will merge its off-patent drug business with generic drugmaker Mylan to create a global leader in low-cost treatment.